Abstract: A new radical inhibitor, a composition containing the new radical inhibitor, and a radical generation inhibition method using the new radical inhibitor are provided. A radical inhibitor according to the present invention contains a salen complex compound of a bivalent metal.

Abstract: A metal-salen complex compound responsive drug, which has an antidotal property capable of neutralizing cytotoxicity of a metal-salen complex compound, and an intra-corporeal behavior control system for the metal-salen complex compound are provided. This metal-salen complex compound responsive drug contains an effective amount of a metal chelating agent to suppress side effects by the metal-salen complex compound.

Abstract: It is intended to provide a drug delivery system which makes it possible to solve the existing technical problems and is easily usable in practice. A drug, which comprises an organic compound or an inorganic compound and has been magnetized by modifying a side chain and/or crosslinking side chains, is induced by a magnetic force into target tissues or an affected part.

Abstract: A metal-salen complex compound, which exhibits excellent noninvasiveness and can be efficiently transferred to an affected site, a local anesthetic containing this metal-salen complex compound, and an antineoplastic drug containing this metal-salen complex compound are provided. Regarding the metal-salen complex compound, a metal atom part in each of two molecules of a metal-salen complex or a derivative of the metal-salen complex is dimerized via water, and the metal-salen complex compound is mixed with a base to produce an ointment.

Abstract: A charging apparatus includes: a charging unit charging a rechargeable battery; a fan to send air to the rechargeable battery; a control unit adapted to activate the fan when a predetermined cooling-execution condition is satisfied after initiation of charging the rechargeable battery by the charging unit and to deactivate the fan when a predetermined maximum cooling period of time is elapsed from completion of charging the rechargeable battery by the charging unit even when the predetermined cooling-execution condition has been satisfied after completion of charging the rechargeable battery by the charging unit; an information obtaining unit configured to obtain cooling-performance information that represents coolability of the rechargeable battery; and a setting unit configured to set the maximum cooling period of time based upon the cooling-performance information obtained by the information obtaining unit.

Abstract: It is intended to provide a drug delivery system which makes it possible to solve the existing technical problems and is easily usable in practice. A drug, which comprises an organic compound or an inorganic compound and has been magnetized by modifying a side chain and/or crosslinking side chains, is induced by a magnetic force into target tissues or an affected part.

Abstract: A charger in one aspect of the present invention includes: a connecting portion, two protection devices, a charging device, a control device, and a voltage detection device. A first protection device is configured such that its power consumption in a charging inhibited state is lower than that in a charging permitted state. A second protection device is configured such that its power consumption in the permitted state is lower than that in the inhibited state. The control device is configured to respectively set, when the battery is not connected to the connecting portion, the first protection device to the inhibited state and the second protection device to the permitted state, and thereafter switch, when the voltage value of the charging path detected by the voltage detection device is equal to or greater than a predetermined specified voltage value, the second protection device to the inhibited state.

Abstract: The molecular structures of metal-salen complexes which exerts pharmacological effects are clarified and the metal-salen complexes having such molecular structures and their derivatives are provided. A metal-salen complex compound is characterized in that a metal atom part in each of multiple molecules of the metal-salen complex or its derivative is multimerized via water.

Abstract: The present invention provides a metal-salen complex compound having a controlled grain size that enables the metal-salen complex compound to exert its pharmacological effects as a medicine, at a target region. This metal-salen complex compound is composed of the following that has a crystal grain size of 8 ?m or less, and that is represented by the chemical formula below. N,N?-Bis(salicylidene)ethylenediamine metal M is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd.

Abstract: A femto base station according to the present invention includes: a downlink perch channel signal transmission power controller unit configured to change a transmission power of a downlink perch channel signal when a first condition is satisfied; and an uplink reception sensitivity controller unit configured to change an uplink reception sensitivity when a second condition is satisfied after the first condition is satisfied.

Abstract: A receiving apparatus for receiving a downlink signal in which pilot symbols are mapped discontinuously, includes: a unit configured to extract reference signals from the downlink signal that is Fourier transformed by a Fourier transform unit; a unit configured to generate a first signal having a first window size by arranging the extracted reference signals on the frequency axis and by performing inverse Fourier transform on the reference signals; a unit configured to divide the first signal into a plurality of signals to extract a signal included in a second window; a unit configured to generate a second signal that includes the signal included in the second window and that has a window size similar to the first window size; a Fourier transform unit configured to generate a third signal from the second signal; and a unit configured to calculate received power based on the third signal.

Abstract: A charging apparatus for charging a battery includes: a control unit that obtains information indicating a status of the battery from the battery and controls permitting or prohibiting charging the battery depending on whether or not the obtained information satisfies a predetermined first condition; a charging detecting unit that detects whether or not the battery is being charged; a charging discontinuing unit that obtains the information indicating the status of the battery from the battery and discontinues charging the battery independently of the control by the control unit to permit or prohibit charging when the obtained information satisfies a predetermined second condition; and a diagnosing unit that inputs diagnostic information satisfying the second condition to the charging discontinuing unit in addition to the information indicating the status of the battery or as a replacement for the information indicating the battery status based upon information entered from the control unit.

Abstract: The present invention provides a novel compound capable of inhibiting cardiac adenylyl cyclase. The present invention relates to a compound represented by the following formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof: where R1, R2 and R3 each independently represent a hydrogen atom or an acyl group having an acidic or basic substituent, provided that all of R1, R2 and R3 are not simultaneously a hydrogen atom. The present invention also provides a modulator of adenylyl cyclase activity, a pharmaceutical composition and a food composition, all of which comprise the above-described compound or a pharmaceutically acceptable salt, ester or solvate thereof.

Abstract: A reception device calculates a radio quality in a downlink by using a plurality of pilot symbols transmitted from a base station. The reception device includes a correlation calculation unit and a radio quality calculation unit. The correlation calculation unit calculates a correlation value between a first pilot symbol and a second pilot symbol on a time axis or a correlation value there between on a frequency axis. If the correlation value obtained by the correlation calculation unit exceeds a predetermined threshold value, the radio quality calculation unit calculates a radio quality in the downlink by using a reception quality of the first pilot symbol and a reception quality of the second pilot symbol.

Abstract: A drug containing a metal-salen complex compound which is effective for a brain tumor is provided. The present invention is an anti-brain-tumor drug containing a metal-salen complex compound represented by the following Chemical Formula (I). In the formula, M represents a metal atom which is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd, and X represents a halogen atom.

Abstract: It is an object of the present invention to extend the usefulness of an iron-salen complex. The present invention is a new fluorochrome material containing Chemical Formula (I) below. However, M is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd.

Abstract: A metal-salen complex derivative with an excellent yield and stability is provided and a method for producing such a metal-salen complex derivative is provided. The present invention provides: metal-salen complex derivative obtained by allowing a target component composed of at least one of an enzyme, an antibody, an antigen, a peptide, an amino acid, an oligonucleotide, a protein, a nucleic acid, and a medical molecule to bind to a metal-salen complex via an amide bond or a disulfide bond; a method for producing such a metal-salen complex derivative.

Abstract: It is intended to provide a drug delivery system which makes it possible to solve the existing technical problems and is easily usable in practice. A drug, which comprises an organic compound or an inorganic compound and has been magnetized by modifying a side chain and/or crosslinking side chains, is induced by a magnetic force into target tissues or an affected part.

Abstract: In this invention, a channel estimation value of data symbols of a data channel is calculated by weighting and averaging pilot symbols in a parallel time multiplexing method. Also, a channel estimation value of data symbols during each data symbol interval is calculated by dividing data symbols in a slot into a plurality of data symbol intervals, selecting pilot symbols suitable for calculation of a channel estimation value of data symbols during each data symbol interval and weighting and averaging that pilot symbols. Also, a fading frequency is detected based on an inner product value of pilot symbols. Weighting factors are changed based on the detected fading frequency. Also, a channel estimation value is calculated by weighting and averaging pilot signals using a plurality of weighting sequences. The calculated channel estimation value is used to demodulate received data. The output data with the highest quality is selected by judging reliability of these plurality of demodulated data.

Abstract: A magnetic body may be suitably applied to a drug delivery system using magnetism. Furthermore, a drug delivery control device allows the magnetic body to be suitably applied to drug delivery. The magnetic body includes a magnet and a cover part attached to an edge of the magnet. The cover part is composed of a material with high magnetic permeability, and a ratio of a length to a radius of the cover part is 10:1 to 7:3. The drug delivery control device includes the magnetic body, a head for supporting the magnetic body and a drive mechanism of the head that causes the head to operate along a projected region formed by the affected area with respect to a surface of a tissue. A magnetic field is applied from the magnetic body to the affected area where a magnetic drug is administered.